Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma

Melanoma Clinical Trial

Official title:

Phase II Study of MS-275, a Histone Deacetylase Inhibitor, Comparing 2 Dosage Schedules in Patients With Metastatic Melanoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00185302
• Other study ID #: 91410
• Secondary ID: 2004-002395-4130
• Status: Completed
• Phase: Phase 2
• First received: September 12, 2005
• Last updated: December 10, 2015
• Start date: December 2004
• Est. completion date: July 2006

Study information

• Verified date: December 2015
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

Primary objective: To evaluate the efficacy of two different dosing schedules of MS-275 in subjects with metastatic melanoma Secondary objectives: To evaluate the safety and to assess the pharmacokinetic profile of MS-275 in subjects with metastatic melanoma

Description:

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: July 2006
• Est. primary completion date: July 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult subjects with Stage III or IV non-resectable nonuveal (cutaneous or mucosal) metastatic melanoma who had received at least one but no more than two previous systemic therapies (immunotherapy and/or chemotherapy) for metastatic disease and who had not responded to or who had progressed after their most recent therapy were eligible for enrollment

• Presence of at least one lesion fulfilling the minimum Response Evaluation Criteria in Solid Tumors (RECIST) size requirements for a target lesion - Use of highly effective birth control methods in females of child-bearing potential

• Able to undergo either contrast enhanced computed tomography (CT) scan or contrast enhanced magnetic resonance imaging (MRI) scan for tumor assessment

• Life expectancy greater than 3 months

• Adequate organ and bone marrow functions as defined below: absolute neutrophil count = 1500 /µL, platelets = 100,000 /µL, creatinine = 1.5 × upper limit of normal (ULN) or measured creatinine clearance of = 60 mL/min x 1.73 m2 body surface area, total bilirubin = 1.5 times ULN, aspartate aminotransferase or serum glutamic oxalacetic transaminase/alanine aminotransferase or serum glutamic pyruvic transaminase* = 2.5 times ULN

• Negative serum pregnancy test within 2 weeks prior to receiving the first dose of study drug in female subjects of childbearing potential. Agreement to use a highly effective method of birth control throughout the study period and 3 months thereafter for sexually active males and females of childbearing potentia

Exclusion Criteria:

• Active malignancy in the last five years

• Pregnancy, breast feeding

• HIV infection

• Brain metastasis

• Concomitant use of corticosteroids or valproic acid

• Uncontrolled intercurrent illness

• Diagnosis of uveal melanoma

• Eastern Cooperative Oncology Group performance status = 2

• Ongoing effects from previous investigational drug studies or concomitant participation in other investigational drug studies

• Prior use of MS-275 or any other HDAC inhibitor

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to MS-275

• Anticancer therapy

• Active gastrointestinal conditions that might predispose for poor drug absorption

• Major surgery within 4 weeks prior to enrollment

• Hypophosphatemia < 2.5 mg/dL at screening, if not corrected in the screening period

• Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
• Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall tumor response rate (the proportion of subjects with the best tumor response of PR or CR within the first 6 cycles of treatment)		Baseline, 8, 16, 24, 32 weeks (cycle 6)	No
Secondary	Time to tumor progression		Baseline, every 8 weeks until progression	No
Secondary	Survival		At 6 months	No
Secondary	Tumor response rate at each tumor assessment time point (CR/PR/SD/PD/not assessable)		At baseline and repeated every 2 cycles until tumor progression between Day 22 of even numbered cycles and Day 1 of subsequent odd numbered cycle and also at EOT and F-up visiit (90 days after the EOT and every 3 months until disease progression)	No
Secondary	Time to death		Baseline, every 8 weeks until death	No
Secondary	Number of participants with adverse events		Approximately 8-64 weeks	Yes

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find information about studies related to Bayer Healthcare products conducted in Europe.
•   Click here to find results for studies related to Bayer Healthcare products.